Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
Yuankai Shi, Gongyan Chen(Harbin Medical University), Xiang Wang(Xuzhou Central Hospital), Yunpeng Liu(First Hospital of China Medical University), Lin Wu(Hunan Cancer Hospital), Yanrong Hao(The People's Hospital of Guangxi Zhuang Autonomous Region), Chunling Liu(Xinjiang Medical University), Shuyang Zhu(Xuzhou Medical College), Xiaodong Zhang(Nantong Tumor Hospital), Yuping Li(First Affiliated Hospital of Wenzhou Medical University), Jiwei Liu(Dalian Medical University), Lejie Cao, Ying Cheng(Jilin Province Tumor Hospital), Hui Zhao(Anhui University), Shucai Zhang(Beijing Chest Hospital), Aimin Zang(Affiliated Hospital of Hebei University), Jiuwei Cui(Jilin University), Jian Feng(Nantong University), Nong Yang(Hunan Cancer Hospital), Fei Liu, Yong Jiang, Chuan Gu
Cited by 224
Abstract
Related Papers
No related papers found
Powered by citation graph analysis